Abstract:A series of 4-thiazolinone derivatives (D1-D58) were designed and synthesized. All of the derivatives were evaluated in vitro for neuraminidase (NA) inhibitory activities against influenza virus A (H1N1), and the inhibitory activities of the five most potent compounds were further evaluated on NA from two different influenza viral subtypes (H3N2 and B), and then their in vitro anti-viral activities were evaluated using the cytopathic effect (CPE) reduction assay. The results showed that the majority of the target compounds exhibited moderate to good NA inhibitory activity. Compound D18 presented the most potent inhibitory activity with IC50 values of 13.06 μM against influenza H1N1 subtype. Among the selected compounds, D18 and D41 turned out to be the most potent inhibitors against influenza virus H3N2 subtype (IC50 = 15.00 μM and IC50 = 14.97 μM, respectively). D25 was the most potent compound against influenza B subtype (IC50 = 16.09 μM). In addition, D41 showed low toxicity and greater potency than reference compounds Oseltamivir and Amantadine against N1-H275Y variant in cellular assays. The structure-activity relationship (SAR) analysis showed that introducing 4-CO2H, 4-OH, 3-OCH3-4-OH substituted benzyl methylene can greatly improve the activity of 4-thiazolinones. Further SAR analysis indicated that 4-thiazolinone and ferulic acid fragments are necessary fragments of target compounds for inhibiting NA. Molecular docking was performed to study the interaction between compound D41 and the active site of NA. This study may providing important information for new drug development for anti-influenza virus including mutant influenza virus.

Further Discovery of Caffeic Acid Derivatives As Novel Influenza Neuraminidase Inhibitors

Caffeic Acid Derivatives: A New Type of Influenza Neuraminidase Inhibitors

Bioassay of ferulic acid derivatives as influenza neuraminidase inhibitors.

Structure-based methoxyflavone derivatives with potent inhibitory activity against various influenza neuraminidases

Studies on synthesis and structure-activity relationship (SAR) of derivatives of a new natural product from marine fungi as inhibitors of influenza virus neuraminidase.

Structure−Activity Relationship Studies of Novel Carbocyclic Influenza Neuraminidase Inhibitors

Discovery of Neuraminidase Inhibitors based on 3D-QSAR, Molecular Docking and MD Simulations

Design,Synthesis and Anti-influenza Activities of Novel Neuraminidase Inhibitors

Design, synthesis, bioactivity, and DFT calculation of 2-thiazolyl-hydrazone derivatives as influenza neuraminidase inhibitors

Identification of C5-NH2 Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability

Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-Cavity

Design and One-Pot Synthesis of 2-Thiazolylhydrazone Derivatives As Influenza Neuraminidase Inhibitors.

In Vitro Anti-Viral Activities and Structure-Activity Relationship Studies of Flavones and Dihydroflavone Derivatives As Influenza Virus Potential Neuraminidase Inhibitors

Design, Synthesis, and Biological Activity of Thiazole Derivatives As Novel Influenza Neuraminidase Inhibitors

Discovery of novel thiophene derivatives as potent neuraminidase inhibitors

Design, Synthesis and Biological Evaluation of "Multi-Site"-binding Influenza Virus Neuraminidase Inhibitors.

Design, synthesis, and preliminary evaluation of new pyrrolidine derivatives as neuraminidase inhibitors.

Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity

A Novel N-heterocycles Substituted Oseltamivir Derivatives As Potent Inhibitors of Influenza Virus Neuraminidase: Discovery, Synthesis and Biological Evaluation

Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors

Design, Synthesis and Biological Evaluation of Honokiol Derivatives As Influenza Neuraminidase Inhibitors.